Tech Company Financing Transactions
Evergreen Theragnostics Funding Round
Evergreen Theragnostics secured a $15 million Series B funding round on 3/13/2023. Backers included private investors.
Transaction Overview
Company Name
Announced On
3/13/2023
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Proceeds Purpose
The company will also use funds from the recent capital raise to prepare for the launch of Ga-68 DOTATOC, if approved. Activities will include building our commercial capabilities and staffing, as well as inventory build. The product is planned to be available through Evergreen's radiopharmacy partners around the country.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
27 Commerce Street
Springfield, NJ 07081
USA
Springfield, NJ 07081
USA
Phone
Website
Email Address
Overview
Evergreen Theragnostics is a radiopharmaceutical company focused on improving the available options for cancer patients through radiopharmaceuticals. We are engaged in three core areas: CDM: Contract Development and Manufacturing of radio pharmaceuticals. Products: Development and commercialization of radiopharmaceutical products (incl. Ga-68 DOTATIOC). Discovery: Discovery and development of novel radiopharmaceuticals to address unmet clinical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Cook
Chief Financial Officer
Alex Agnoletto
Chief Scientific Officer
Thomas Reiner
Browse more venture capital transactions:
Prev: 3/13/2023: Green Li-ion venture capital transaction
Next: 3/13/2023: Saasguru venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs